drugset
drugset / Trial / NCT04918173

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

NCT04918173 ↗

Phase 3 Recruiting 38 enrolled Octapharma
NaSingle-groupOpen-labelPrevention

Summary

The goal of this study is to assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under when they receive Atenativ for surgical procedures or parturition.

Timeline

Start
2022-07-01
Primary completion
2026-12-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atenativ Protein / enzyme biologic 60 iu/kg Intravenous

Indications

hereditary antithrombin deficiency